阿尔茨海默病中的生物材料:一种抗神经炎症的视角
Nanqu Huang1, Wendi Huang2, Mei Wang2
1National Drug Clinical Trial Institution, Third Affiliated Hospital of Zunyi Medical University (The First People's Hospital of Zunyi), Zunyi, Guizhou, 563000, China.
Advanced healthcare materials
|June 8, 2025
概括
生物材料为阿尔茨海默病 (AD) 中的神经炎症治疗提供了有针对性的交付. 在临床转化方面仍然存在挑战,包括生物相容性和血脑屏障 (BBB) 透.
科学领域:
- 神经科学是一个神经科学.
- 生物材料科学 生物材料科学
- 药理学 药理学是指药理学的学科.
背景情况:
- 神经炎症是阿尔茨海默病 (AD) 进展的关键驱动因素.
- 过度活跃的炎症导致神经元损伤,需要针对性的抗炎症策略.
研究的目的:
- 审查最近基于生物材料的神经炎症治疗方法在神经系统疾病中的进展.
- 突出将这些疗法转化为临床实践的机会和挑战.
主要方法:
- 对神经炎症生物材料的临床前和临床研究的综述.
- 分析各种生物材料类型:纳米粒子 (NP),水凝,支架,纳米纤维和外体.
- 评估治疗传递机制和组织修复支持.
主要成果:
- 生物材料能够准确地,局部地提供治疗药物,调节神经炎症.
- 纳米粒子有助于通过血脑屏障 (BBB) 提供向药物.
- 水凝和支架提供持续释放,并支持神经再生.
结论:
- 生物材料显示出治疗AD和其他神经系统疾病中神经炎症的巨大潜力.
- 临床翻译面临的障碍包括生物相容性,BBB透和适应性炎症反应.
- 需要进一步的研究来克服挑战,并实现生物材料的全部治疗潜力.
相关概念视频
01:26Alzheimer's Disease: Overview
686
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
686
01:22Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265